- Home
- YDDL vs CLLS Comparison
YDDL vs CLLS Comparison
Compare YDDL & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YDDL | CLLS |
|---|---|---|
| Founded | 2014 | 1999 |
| Country | Philippines | France |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 358.9M | 384.3M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | YDDL | CLLS |
|---|---|---|
| Price | $15.34 | $3.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | ★ 304.7K | 46.4K |
| Earning Date | 05-25-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $40.85 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.61 | $1.17 |
| 52 Week High | $15.90 | $5.48 |
Technical Indicators
Market Signals| Indicator | YDDL | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 71.60 | 50.31 |
| Support Level | $4.77 | $3.32 |
| Resistance Level | $15.90 | $3.83 |
| Average True Range (ATR) | 1.94 | 0.20 |
| MACD | 0.35 | 0.03 |
| Stochastic Oscillator | 89.67 | 67.35 |
Price Performance
Historical ComparisonAbout YDDL One and One Green Technologies. Inc Class A Ordinary Shares
One and one Green Technologies Inc is engaged in recycling, production, and trading of recycled scrap metals in the Republic of Philippines. The company process raw materials and generate final products that include copper alloy ingot, aluminum scrapes, plastic beads, and others. It provides economical and flexible solutions to the challenges of electronic waste, metal scrap and industrial recycling. By providing lower-cost alternatives for processing recycled materials, It is not only Contributing to environmental sustainability but also highlight its role as a modern and specialized recycling company.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.